Buyout Of BioClinica - Law Firm Challenges Fairness Of Price On Behalf Of Shareholders

NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announces that it is investigating the acquisition of BioClinica, Inc.  BioClinica, Inc. (NASDAQ: BIOC), announced that it has entered into a definitive agreement to be acquired by a holding company controlled by JLL Partners, Inc., a leading private equity firm.

Under terms of the BioClinica agreement, the holding company will commence a cash tender offer to purchase all of BioClinica's common stock at an offer price of $7.25 a share, which results in an equity value of approximately $123 million.

The investigation concerns, among other things, whether the consideration to be paid to BIOC shareholders is unfair, inadequate, and substantially below the fair or inherent value of Duff.   Indeed, analysts have projected that the true going forward inherent value of the company is worth at least $9 per share. The investigation further concerns whether the senior management of BIOC may have breached their fiduciary duties by not acting in shareholders' best interests in connection with the sale process of BIOC since they will be joining the buyout group.

If you own BIOC common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact

Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.

Contacts
Tripp Levy PLLC
Tripp Levy, 877-772-3975
[email protected]

SOURCE Tripp Levy PLLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED